本文選題：膠質(zhì)瘤　切入點(diǎn)：細(xì)胞增殖　出處：《河北醫(yī)科大學(xué)》2016年博士論文

【摘要】：膠質(zhì)瘤是人類中樞神經(jīng)系統(tǒng)中最為常見的原發(fā)性惡性腫瘤,約占顱內(nèi)腫瘤的40%~60%。目前對(duì)膠質(zhì)瘤患者普遍采用手術(shù)切除聯(lián)合術(shù)后放化療等綜合治療方法。雖然近年來,神經(jīng)影像技術(shù)、顯微外科技術(shù)以及放化療治療方案等多方面均取得了突飛猛進(jìn)的發(fā)展,但對(duì)于膠質(zhì)瘤患者,尤其是高級(jí)別的膠質(zhì)瘤患者,預(yù)后仍然不佳。膠質(zhì)母細(xì)胞瘤(WHOⅣ級(jí))患者術(shù)后復(fù)發(fā)率仍接近100%,中位生存時(shí)間少于1年。文獻(xiàn)報(bào)道,低級(jí)別膠質(zhì)瘤患者平均生存時(shí)間為3~5年,而高級(jí)別患者則是1~2年。治療效果的不佳主要是由于膠質(zhì)瘤細(xì)胞具有高度侵襲、增殖、遷移能力以及凋亡抑制的特性,決定了膠質(zhì)瘤不可能單純通過外科方法得到治愈,而目前的放化療治療也無法滿意控制膠質(zhì)瘤的發(fā)展。因此,深入了解膠質(zhì)瘤發(fā)生發(fā)展機(jī)制,研究靶向藥物以特異性地抑制甚至滅活殘存瘤細(xì)胞,是未來膠質(zhì)瘤治療的方向。目前已經(jīng)發(fā)現(xiàn)許多與腫瘤相關(guān)的基因及蛋白因子,有些已經(jīng)研究的比較深入,一部分新型抗腫瘤藥物已應(yīng)用臨床并顯著改善預(yù)后。但是針對(duì)膠質(zhì)瘤的藥物研究大多仍處于實(shí)驗(yàn)的初級(jí)階段,仍需進(jìn)一步研究探索。mi RNA即微小RNA(microRNA),是一類新近發(fā)現(xiàn)的、內(nèi)源性、非蛋白質(zhì)編碼RNA,因其在各種病理生理過程中的強(qiáng)大作用逐漸受到重視。文獻(xiàn)指出,miR-95-3p在直腸癌、胰腺癌、乳腺癌及前列腺癌等癌癥中具有致癌作用。考慮到miR-95-3p尚未在膠質(zhì)瘤細(xì)胞中進(jìn)行過研究,故在本實(shí)驗(yàn)中我們選取miR-95-3p作為對(duì)象,并通過MTT實(shí)驗(yàn),流式細(xì)胞技術(shù)以及Transwell實(shí)驗(yàn)探討其對(duì)于膠質(zhì)瘤的作用。CELF2(CUGBP-and ETR-3-like family)為一組RNA連接蛋白,包含眾多與基因轉(zhuǎn)錄后調(diào)控相關(guān)的蛋白。研究表明,CELF2編碼基因位于10號(hào)染色體上,該染色體在60%的低級(jí)別膠質(zhì)瘤中呈單體型,并在80%的高級(jí)別膠質(zhì)瘤中部分缺失,我們因此猜測CELF2與膠質(zhì)瘤的發(fā)生發(fā)展可能相關(guān)。由于CELF2出現(xiàn)在Targetscan的預(yù)測結(jié)果中,我們進(jìn)一步研究其與miR-95-3p的關(guān)系。實(shí)驗(yàn)中我們通過熒光素酶報(bào)告基因?qū)嶒?yàn)確定mir-95-3p與celf2的靶向作用關(guān)系,并分析兩者表達(dá)量的相關(guān)性進(jìn)一步證實(shí)兩者相關(guān)性。最后通過復(fù)活實(shí)驗(yàn)證實(shí)mir-95-3p對(duì)膠質(zhì)瘤的作用是通過靶向調(diào)控celf2引起的。第一部分mir-95-3p在人腦膠質(zhì)瘤組織中的表達(dá)及其與膠質(zhì)瘤病理級(jí)別的相關(guān)性目的:研究mir-95-3p在人腦膠質(zhì)瘤組織中的表達(dá),并分析mir-95-3p的表達(dá)與膠質(zhì)瘤病理級(jí)別的關(guān)系。方法:1組織標(biāo)本的采集:35例膠質(zhì)瘤樣本及15例非腫瘤腦組織樣本均于2014年采集自河北醫(yī)科大學(xué)第二醫(yī)院神經(jīng)外科。包括19名女性,31名男性,年齡從18至68歲,共收集膠質(zhì)瘤樣本35例,其中Ⅰ級(jí)膠質(zhì)瘤4例、ii級(jí)5例、iii級(jí)17例、iv級(jí)9例,均由術(shù)中切除獲得。15例非腫瘤腦組織樣本來自于對(duì)嚴(yán)重的腦外傷患者進(jìn)行的顱內(nèi)減壓術(shù)。診斷結(jié)果均由2位病理醫(yī)師根據(jù)who分級(jí)指導(dǎo)得出。所有樣本在采集后立即保存至-80℃液氮中。2樣本mir-95-3p表達(dá)水平的測定:反轉(zhuǎn)錄定量聚合酶鏈反應(yīng)(qrt-pcr)方法測定35例膠質(zhì)瘤樣本以及15例非腫瘤腦組織樣本中的mir-95-3p含量。3相關(guān)性分析:應(yīng)用t檢驗(yàn)分析膠質(zhì)瘤中mir-95-3p含量與膠質(zhì)瘤級(jí)別之間的關(guān)系。結(jié)果:1qrt-pcr結(jié)果:膠質(zhì)瘤組織與非腫瘤腦組織中mir-95-3p表達(dá)量具有顯著性差異。與對(duì)照非腫瘤腦組織相比,膠質(zhì)瘤組織中mir-95-3p含量顯著升高,差別具有統(tǒng)計(jì)學(xué)意義(p0.001)。2t檢驗(yàn)結(jié)果:低級(jí)別膠質(zhì)瘤(whoⅠ、Ⅱ級(jí))、高級(jí)別膠質(zhì)瘤(whoⅢ、Ⅳ級(jí))及非腫瘤腦組織中mir-95-3p表達(dá)量具有顯著性差異。在高級(jí)別膠質(zhì)瘤組織中mir-95-3p的含量較低級(jí)別更高。結(jié)論:1mir-95-3p在人腦膠質(zhì)瘤組織中高表達(dá),且其表達(dá)量隨著膠質(zhì)瘤級(jí)別的升高而升高。高級(jí)別膠質(zhì)瘤mir-95-3p的表達(dá)量要高于低級(jí)別膠質(zhì)瘤,差別具有統(tǒng)計(jì)學(xué)意義。2mir-95-3p的表達(dá)水平與膠質(zhì)瘤的級(jí)別呈顯著的正相關(guān),提示mir-95-3p可能成為膠質(zhì)瘤臨床分級(jí)的分子標(biāo)志物。第二部分mir-95-3p對(duì)膠質(zhì)瘤細(xì)胞生物學(xué)活性的影響目的:研究mir-95-3p對(duì)u87和u251細(xì)胞的增殖、侵襲、凋亡及細(xì)胞周期等方面的影響。方法:1培養(yǎng)u87和u251細(xì)胞系用于體外功能學(xué)實(shí)驗(yàn)。向?qū)嶒?yàn)組中轉(zhuǎn)染mir-95-3paso以降低細(xì)胞內(nèi)mir-95-3p的表達(dá)。對(duì)照組轉(zhuǎn)染ctrlaso。2進(jìn)行mtt實(shí)驗(yàn)研究降低mir-95-3p表達(dá)后膠質(zhì)瘤細(xì)胞增殖能力的變化。3進(jìn)行流式細(xì)胞實(shí)驗(yàn)研究降低mir-95-3p表達(dá)后膠質(zhì)瘤細(xì)胞周期及凋亡能力的變化。4進(jìn)行transwell實(shí)驗(yàn)研究降低mir-95-3p表達(dá)后膠質(zhì)瘤細(xì)胞侵襲能力的變化。結(jié)果:1qrt-pcr結(jié)果顯示,轉(zhuǎn)染mir-95-3paso后,u87及u251細(xì)胞內(nèi)mir-95-3p的表達(dá)量顯著降低(p0.05)。2mtt實(shí)驗(yàn)結(jié)果顯示,降低mir-95-3p表達(dá)后,u87及u251細(xì)胞增殖能力顯著降低(p0.05)。3流式細(xì)胞實(shí)驗(yàn)結(jié)果顯示,降低mir-95-3p表達(dá)后,u87及u251細(xì)胞周期無明顯改變,凋亡增殖能力顯著增高(p0.05)。4transwell實(shí)驗(yàn)結(jié)果顯示,降低mir-95-3p表達(dá)后,u87及u251細(xì)胞侵襲能力顯著降低(p0.05)。結(jié)論:降低mir-95-3p表達(dá),可以使u87及u251細(xì)胞增殖及侵襲能力顯著降低,凋亡能力顯著增高,細(xì)胞周期無明顯差別。mir-95-3p可以影響膠質(zhì)瘤細(xì)胞的增殖、侵襲及凋亡水平。第三部分celf2為mir-95-3p的下游靶基因目的:尋找mir-95-3p的下游作用靶點(diǎn),進(jìn)一步了解mir-95-3p對(duì)膠質(zhì)瘤生物學(xué)影響的作用機(jī)制。方法:1使用在線工具targetscan預(yù)測mir-95-3p的下游作用靶點(diǎn),并根據(jù)文獻(xiàn)資料篩選結(jié)果。2雙熒光素酶報(bào)告基因?qū)嶒?yàn)驗(yàn)證mir-95-3p與celf2的靶向作用關(guān)系。3應(yīng)用反轉(zhuǎn)錄定量聚合酶鏈反應(yīng)(qrt-pcr)及蛋白質(zhì)免疫印跡(westernblot)方法檢測mir-95-3p與celf2在u87及u251細(xì)胞中的表達(dá)量,并分析兩者的相關(guān)性。結(jié)果:1根據(jù)targetscan的預(yù)測結(jié)果,并結(jié)合相關(guān)文獻(xiàn)資料,猜測celf2上可能存在mir-95-3p的靶向作用位點(diǎn)。2相對(duì)于mir-95-3p反義寡核苷酸(mir-95-3paso),對(duì)照組中共轉(zhuǎn)染mir-95-3p與ctrlaso可以顯著抑制熒光素酶活性,而突變靶位點(diǎn)后此抑制作用消失。3mir-95-3p與celf2在u87及u251中的表達(dá)量呈負(fù)相關(guān)。結(jié)論:celf2的mrna中存在mir-95-3p在膠質(zhì)瘤中的靶向作用位點(diǎn)。第四部分mir-95-3p通過調(diào)控celf2影響膠質(zhì)瘤細(xì)胞增殖、侵襲、凋亡等的生物學(xué)活性目的:證實(shí)mir-95-3p對(duì)膠質(zhì)瘤的生物學(xué)活性影響是通過調(diào)控celf2而完成的。方法:1向u251細(xì)胞內(nèi)轉(zhuǎn)染mir-95-3paso后,同時(shí)轉(zhuǎn)染小干擾rna(smallinterferingrna,sirna),以降低細(xì)胞中celf2的含量。2進(jìn)行mtt實(shí)驗(yàn),實(shí)驗(yàn)組共轉(zhuǎn)染mir-95-3paso與celf2sirna,對(duì)照組共轉(zhuǎn)染mir-95-3p與ctrlsirna,檢測u251細(xì)胞增殖能力的改變。3進(jìn)行流式細(xì)胞實(shí)驗(yàn),實(shí)驗(yàn)組共轉(zhuǎn)染mir-95-3paso與celf2sirna,對(duì)照組共轉(zhuǎn)染mir-95-3p與ctrlsirna,檢測u251細(xì)胞凋亡能力的改變。4進(jìn)行transwell實(shí)驗(yàn),實(shí)驗(yàn)組共轉(zhuǎn)染mir-95-3paso與celf2sirna,對(duì)照組共轉(zhuǎn)染mir-95-3p與ctrlsirna,檢測u251細(xì)胞侵襲能力的改變。1 Western blot實(shí)驗(yàn)證實(shí)轉(zhuǎn)染CELF2 siRNA后,U251細(xì)胞內(nèi)CELF2含量顯著降低(P0.05)。2 MTT實(shí)驗(yàn)結(jié)果顯示,相對(duì)于對(duì)照組,實(shí)驗(yàn)組中U251細(xì)胞增殖能力明顯降低(P0.05)。3流式細(xì)胞實(shí)驗(yàn)結(jié)果顯示,相對(duì)于對(duì)照組,實(shí)驗(yàn)組中U251細(xì)胞凋亡能力明顯增高(P0.05)。4 Transwell實(shí)驗(yàn)結(jié)果顯示,相對(duì)于對(duì)照組,實(shí)驗(yàn)組中U251細(xì)胞侵襲能力明顯降低(P0.05)。結(jié)論:miR-95-3p是通過調(diào)控CELF2的表達(dá)而影響膠質(zhì)瘤增殖、凋亡、侵襲能力改變的。
[Abstract]:Glioma is the human central nervous system is the most common primary malignant tumor, accounnting 40%~60%. of glioma patients commonly used surgery chemotherapy and other comprehensive treatment method of resection. Although in recent years, neuroimaging techniques, microsurgical technique and chemoradiotherapy achieved etc. the rapid development, but for glioma patients, especially in patients with high grade gliomas, the prognosis is still poor. Glioblastoma (WHO IV) recurrence rate is close to 100%, the median survival time of less than 1 years. The literature reported that patients with low grade gliomas the average survival time was 3~5 however, patients with high grade is 1~2 years. The poor treatment effect is mainly due to glioma cells with high invasion, proliferation, migration and apoptosis characteristics, determines the glioma may not only by Methods surgical cure and chemotherapy in the treatment of current cannot satisfy the development control of glioma. Therefore, in-depth understanding of the occurrence and development mechanism of glioma research, targeted drugs to specifically inhibit or inactivate the residual tumor cells, glioma is the future direction of the treatment. It was found that many tumor related genes and some of the proteins, has been more in-depth, part of a new antitumor drug has clinical application and improve the prognosis. But research on drugs of glioma are still in the primary stage of the experiment, further research is needed to explore the.Mi RNA micro RNA (microRNA), is a newly discovered endogenous non protein. RNA encoding, because of its powerful role in various pathophysiological processes has attracted much attention. The literature pointed out, miR-95-3p in rectal cancer, pancreatic cancer, breast cancer and prostate cancer and other cancers. Taking into account the carcinogenic effect. MiR-95-3p has not been in glioma cells studied in this experiment, we select miR-95-3p as the object, and through the MTT experiment to investigate the effect of.CELF2 glioma cells and Transwell (CUGBP-and ETR-3-like family) flow experiment for a group of RNA binding protein related protein regulation, including many of the post transcriptional gene. The results show that the CELF2 encoding gene is located on chromosome 10, the chromosome haplotype was in low grade glioma in 60%, and 80% in the high grade gliomas excalation, so I guess the occurrence and development of CELF2 and glioma may be related. Because CELF2 appear in the prediction results in Targetscan, we further study the relationship with miR-95-3p. In our experiment by luciferase reporter assay and determine mir-95-3p targeting celf2, and analysis The expression of correlation further confirmed the relationship between them. Finally, the resurrection experiments confirmed that the effect of mir-95-3p on glioma is caused by celf2 to control the target. Part 1 expression of mir-95-3p in human glioma tissues and its correlation with the pathological grade of glioma Objective: To study the expression of mir-95-3p in human glioma tissues, and analysis the relationship between mir-95-3p expression and pathological grade of glioma. Methods: 1 tissue specimens collected: 35 cases of glioma samples and 15 cases of non tumor brain tissue samples were collected in 2014 from the second hospital of Hebei Medical University, Department of neurosurgery. Including 19 women, 31 men, aged from 18 to 68 years, a total of 35 cases of glioma samples, including 4 cases of glioma, 5 cases of grade II, III grade 17 cases, 9 cases of grade IV, were obtained by resection of.15 cases of non tumor brain tissue samples from the patients with severe traumatic brain injury Intracranial decompression performed. According to the WHO grading diagnosis results by 2 pathologists. All the samples that guide preservation to the level of mir-95-3p expression were detected by.2 -80 C in liquid nitrogen immediately after collection: reverse transcription polymerase chain reaction (qRT-PCR) analysis of.3 correlation of mir-95-3p content in 35 cases of glioma and 15 cases of non tumor samples brain tissue samples: application of t test method to analyze the relationship between the content of mir-95-3p in glioma and glioma grade. Results: 1qrt-pcr results: a significant difference of mir-95-3p expression of glioma and non tumor brain tissues. Compared with non tumor brain tissue, the content of mir-95-3p in glioma tissues increased significantly. The difference was statistically significant (p0.001).2t test results: low grade gliomas (who I, II) and high grade gliomas (who III, IV) and non tumor brain tissue of mir-95-3p expression The difference is significant. The content of mir-95-3p in high grade glioma tissues of the lower level higher. Conclusion: high expression of 1mir-95-3p in human glioma tissues, and its expression increased with the glioma grade. The expression of mir-95-3p in high grade gliomas than in low grade gliomas, a significant positive expression was statistically significant difference.2mir-95-3p and glioma grade, suggesting that mir-95-3p may become a molecular marker for glioma clinical classification. The second part: the effect of mir-95-3p on glioma cells Objective: To study the biological activity of mir-95-3p and U251 on U87 cell proliferation, invasion, apoptosis and cell cycle and other aspects of the method. 1: the culture of U87 and U251 cells for in vitro functional experiments. The experimental group was transfected with mir-95-3paso to reduce the expression of mir-95-3p in cells transfected with ctrlaso.2 in the control group MTT experimental study on reducing the change of.3 expression of mir-95-3p glioma cell proliferation by flow cytometry experiments of experimental study of Transwell decreased after glioma cell invasion of the expression of mir-95-3p decreased.4 mir-95-3p expression in glioma cell cycle and apoptosis ability. Results: 1qrt-pcr results showed that after mir-95-3paso transfection, expression U87 and U251 cells significantly decreased mir-95-3p (P0.05).2mtt experimental results show that the decreased expression of mir-95-3p, U87 and U251 Cell proliferation ability decreased significantly (P0.05).3 flow cytometry results showed that decreased expression of mir-95-3p, U87 and U251 no significant changes in the cell cycle, proliferation apoptosis significantly increased (P0.05).4transwell the experimental results show that the reduced expression of mir-95-3p, U87 and the invasion ability of U251 cells was significantly decreased (P0.05). Conclusion: the decreased expression of mir-95-3p, can make u 87 and U251 Cell Proliferation and invasion ability decreased significantly, the apoptosis increased significantly, there was no significant difference in cell cycle of.Mir-95-3p can affect the glioma cell proliferation, invasion and apoptosis level. The third part celf2 is the downstream target genes of mir-95-3p Objective: to find out the mir-95-3p downstream targets, to further understand the mechanism of mir-95-3p effect on glioma biology. Methods: 1 using the online tool targetscan to predict downstream effect of mir-95-3p target, and screening results of mir-95-3p and celf2 to verify the.2 dual luciferase assay targeting.3 by reverse transcription polymerase chain reaction (qRT-PCR) based on the literature and Western blot (Westernblot) method to detect mir-95-3p and celf2 expression in U87 and U251 cells, and to analyze the relationship between them. Results: 1 according to the prediction results of targetscan, and combined with the relevant Literature, guess mir-95-3p might exist on celf2 targeting sites of.2 compared with mir-95-3p antisense oligonucleotide (mir-95-3paso), the control group transfected with mir-95-3p and ctrlaso can significantly inhibit the luciferase activity, and mutation of target sites of this inhibition of the expression of.3mir-95-3p and celf2 disappeared in U87 and in U251 was negatively correlated. Conclusion: mir-95-3p in glioma targeting sites of celf2 mRNA in mir-95-3p. The fourth part through the regulation of celf2 proliferation effect of glioma cell invasion, apoptosis and biological activity Objective: To study the effects of biological activity of mir-95-3p on glioma is completed by the regulation of celf2. Methods: 1 to U251 cells after transfection of mir-95-3paso. At the same time, transfection of small interfering RNA (smallinterferingrna, siRNA), in order to reduce the content of.2 in celf2 cells by MTT experiment, the experimental group were transfected into mir-95-3paso and CE Lf2sirna, the control group were transfected into mir-95-3p and ctrlsirna, U251 to detect the changes of cell proliferation..3 flow cytometry experiment, the experimental group were transfected into mir-95-3paso and celf2sirna, the control group were transfected into mir-95-3p and ctrlsirna, U251 apoptosis detection ability change.4 Transwell experiment, the experimental group were transfected into mir-95-3paso and celf2sirna, CO transfected control group mir-95-3p ctrlsirna and.1 Western blot, change the experimental invasion ability of U251 cells were detected by CELF2 siRNA after transfection confirmed, CELF2 in U251 cells was significantly reduced (P0.05).2 MTT experimental results show that compared with the control group, U251 cell proliferation in experimental group was significantly lower (P0.05).3 flow cytometry results showed that compared with the control U251 group, apoptosis in experimental group was significantly increased (P0.05).4 Transwell experimental results show that compared with the control group, U251 cell infiltration in the experimental group The attack ability was significantly reduced (P0.05). Conclusion: miR-95-3p affects the proliferation, apoptosis, and invasion of glioma by regulating the expression of CELF2.

【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：博士
【學(xué)位授予年份】：2016
【分類號(hào)】：R739.41

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐俊杰;于洪泉;國巍;趙偉;金宏;溫娜;齊玲;;西蘭花多肽對(duì)大鼠C6膠質(zhì)瘤細(xì)胞生長的影響[J];中風(fēng)與神經(jīng)疾病雜志;2012年11期

2 徐俊杰;于洪泉;趙偉;金宏;溫娜;齊玲;劉興吉;;西蘭花多肽對(duì)C6膠質(zhì)瘤細(xì)胞的誘導(dǎo)凋亡作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2013年01期

3 仝海波,江澄川,唐鎮(zhèn)生,金一尊;膠質(zhì)瘤細(xì)胞化學(xué)增敏作用實(shí)驗(yàn)研究[J];山西臨床醫(yī)藥;2000年07期

4 李嗍,王楓,繆珊,駱文靜;過量鋅對(duì)鼠膠質(zhì)瘤細(xì)胞體外生長的影響[J];解放軍預(yù)防醫(yī)學(xué)雜志;2001年04期

5 梁一鳴,郭國慶,鄭少俊,沈偉哉;膠質(zhì)瘤血管內(nèi)皮生長因子表達(dá)的調(diào)節(jié)[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2001年02期

6 曲元明,韓韜,李桂林,王成偉;血管內(nèi)皮細(xì)胞生長因子抗體對(duì)膠質(zhì)瘤生長的影響[J];山東醫(yī)科大學(xué)學(xué)報(bào);2001年02期

7 黃強(qiáng),董軍;膠質(zhì)瘤的分子外科治療[J];中國微侵襲神經(jīng)外科雜志;2001年04期

8 葉明,周岱,周幽心,王瑋,傅建新,黃煜倫;血管內(nèi)皮生長因子在膠質(zhì)瘤中的表達(dá)[J];腫瘤;2002年06期

9 顧宇翔,陳銜城,王宇倩;膠質(zhì)瘤對(duì)親細(xì)胞非均質(zhì)分子脂質(zhì)和幾種藥物敏感性的比較[J];復(fù)旦學(xué)報(bào)(醫(yī)學(xué)版);2003年02期

10 王成偉 ,劉福生 ,曲元明 ,李桂林;血管內(nèi)皮生長因子抗體抑制膠質(zhì)瘤生長的實(shí)驗(yàn)研究[J];中華神經(jīng)外科雜志;2003年01期

相關(guān)會(huì)議論文 前10條

1 李飛;李梅;盧佳友;朱剛;林江凱;孟輝;吳南;陳志;馮華;;脂質(zhì)微區(qū)干擾劑甲基-β-環(huán)糊精影響C6膠質(zhì)瘤細(xì)胞侵襲和遷移的體外實(shí)驗(yàn)研究[A];中國醫(yī)師協(xié)會(huì)神經(jīng)外科醫(yī)師分會(huì)第四屆全國代表大會(huì)論文匯編[C];2009年

2 吳安華;王運(yùn)杰;Ohlfest JR;Wei Chen;Low WC;;膠質(zhì)瘤的生物治療-從實(shí)驗(yàn)室到臨床[A];中華醫(yī)學(xué)會(huì)神經(jīng)外科學(xué)分會(huì)第九次學(xué)術(shù)會(huì)議論文匯編[C];2010年

3 徐宏;韓楊云;孫中書;李新軍;;與膠質(zhì)瘤代謝通路相關(guān)的候選基因篩選[A];中華醫(yī)學(xué)會(huì)神經(jīng)外科學(xué)分會(huì)第九次學(xué)術(shù)會(huì)議論文匯編[C];2010年

4 潘冬生;;多基因修飾膠質(zhì)瘤細(xì)胞疫苗的抗腫瘤免疫反應(yīng)[A];中國醫(yī)師協(xié)會(huì)神經(jīng)外科醫(yī)師分會(huì)第六屆全國代表大會(huì)論文匯編[C];2011年

5 俞文華;車志豪;張祖勇;許培源;陸鏞民;傅林;朱強(qiáng);陳鋒;杜權(quán);;骨橋蛋白在膠質(zhì)瘤細(xì)胞中的表達(dá)及其信號(hào)傳導(dǎo)途徑[A];2005年浙江省神經(jīng)外科學(xué)術(shù)會(huì)議論文匯編[C];2005年

6 張震;徐克;;低強(qiáng)度超聲誘導(dǎo)C6膠質(zhì)瘤細(xì)胞凋亡的體外實(shí)驗(yàn)研究[A];中華醫(yī)學(xué)會(huì)第十三次全國超聲醫(yī)學(xué)學(xué)術(shù)會(huì)議論文匯編[C];2013年

7 蔣偉峰;高方友;尹浩;;白細(xì)胞介素-17及其受體在膠質(zhì)瘤中的表達(dá)及臨床意義[A];2013年貴州省神經(jīng)外科年會(huì)論文集[C];2013年

8 徐慶生;張小兵;周永慶;;膠質(zhì)瘤干細(xì)胞及其放療敏感性[A];2011年浙江省神經(jīng)外科學(xué)學(xué)術(shù)年會(huì)論文匯編[C];2011年

9 楊孔賓;趙世光;劉炳學(xué);陳曉豐;戴欽舜;;K~+通道阻斷劑四乙胺對(duì)大鼠膠質(zhì)瘤細(xì)胞的增殖和凋亡影響[A];中國醫(yī)師協(xié)會(huì)神經(jīng)外科醫(yī)師分會(huì)第四屆全國代表大會(huì)論文匯編[C];2009年

10 黃強(qiáng);;膠質(zhì)瘤生成細(xì)胞研究[A];第三屆中國腫瘤學(xué)術(shù)大會(huì)教育論文集[C];2004年

相關(guān)重要報(bào)紙文章 前5條

1 衣曉峰　馮宇曦;中藥三氧化二砷有望成為治療膠質(zhì)瘤新藥[N];中國醫(yī)藥報(bào);2011年

2 記者 匡遠(yuǎn)深;讓膠質(zhì)瘤干細(xì)胞不再“繁殖”[N];健康報(bào);2011年

3 張獻(xiàn)懷　張文;瘤區(qū)埋雷 持續(xù)殺傷[N];健康報(bào);2007年

4 白毅;人腦膠質(zhì)瘤基礎(chǔ)與應(yīng)用研究喜結(jié)“九大碩果”[N];中國醫(yī)藥報(bào);2006年

5 王德江；劉藏；王貴懷；曹勇；王新生；肖新如;交流最新進(jìn)展 提高診治水平[N];中國醫(yī)藥報(bào);2005年

相關(guān)博士學(xué)位論文 前10條

1 董軍;CUL4B在神經(jīng)膠質(zhì)細(xì)胞瘤中的作用研究[D];山東大學(xué);2015年

2 張睿;循環(huán)miR-221/222在膠質(zhì)瘤診斷與預(yù)后中的價(jià)值與基于CED的中樞神經(jīng)系統(tǒng)給藥新方法的研究[D];山東大學(xué);2015年

3 許森林;ALDH1A1在膠質(zhì)瘤侵襲和結(jié)直腸癌轉(zhuǎn)移中的作用和機(jī)制[D];第三軍醫(yī)大學(xué);2015年

4 王嘯;靶向嵌段共聚物膠束在膠質(zhì)瘤磁共振成像、藥物輸送及治療的應(yīng)用[D];安徽醫(yī)科大學(xué);2015年

5 廖紅展;鋅指轉(zhuǎn)錄因子SNAI2在miR-203的影響下通過上皮間質(zhì)轉(zhuǎn)化參與膠質(zhì)瘤耐藥機(jī)制的調(diào)節(jié)[D];南方醫(yī)科大學(xué);2015年

6 潘俊;IRG1促進(jìn)膠質(zhì)瘤增殖的作用機(jī)制及臨床意義[D];南方醫(yī)科大學(xué);2015年

7 鄭傳宜;膠質(zhì)瘤中GLUT3基因異常表達(dá)的意義及其相關(guān)調(diào)控機(jī)制[D];南方醫(yī)科大學(xué);2015年

8 徐紅超;氬氦冷凍消融聯(lián)合GM-CSF治療膠質(zhì)瘤小鼠的療效及其對(duì)小鼠脾臟樹突狀細(xì)胞免疫功能影響[D];南方醫(yī)科大學(xué);2015年

9 黃素寧;TNFRSF6B在膠質(zhì)瘤中的表達(dá)及對(duì)膠質(zhì)瘤細(xì)胞增殖及凋亡的作用研究[D];南方醫(yī)科大學(xué);2015年

10 熊偉;GBE1在人腦膠質(zhì)細(xì)胞瘤中的表達(dá)及干預(yù)實(shí)驗(yàn)研究[D];第四軍醫(yī)大學(xué);2015年

相關(guān)碩士學(xué)位論文 前10條

1 張大慶;單核細(xì)胞趨化蛋白-1在骨髓間充質(zhì)干細(xì)胞向膠質(zhì)瘤細(xì)胞趨化中的作用研究[D];大連醫(yī)科大學(xué);2012年

2 黃俊龍;ADC值與膠質(zhì)瘤Ki-67、MGMT的相關(guān)性研究[D];福建醫(yī)科大學(xué);2015年

3 李明聰;下調(diào)Pygo2對(duì)U251及U251起源的膠質(zhì)瘤干細(xì)胞生物學(xué)特性的影響[D];福建醫(yī)科大學(xué);2015年

4 徐云峰;膠質(zhì)瘤干細(xì)胞的3D培養(yǎng)及其核酸適體篩選的探索[D];福建醫(yī)科大學(xué);2015年

5 張靜文;T細(xì)胞過繼免疫治療小鼠腦膠質(zhì)瘤原位模型的研究[D];河北醫(yī)科大學(xué);2015年

6 洪宇;膠質(zhì)瘤瘤周水腫、病理級(jí)別、Ki-67表達(dá)三者相關(guān)性研究[D];石河子大學(xué);2015年

7 姬云翔;磷酸化Cx43蛋白在人膠質(zhì)瘤細(xì)胞中表達(dá)及其與腫瘤細(xì)胞增殖相關(guān)性研究[D];石河子大學(xué);2015年

8 朱峰;OPN的異常表達(dá)與膠質(zhì)瘤的相關(guān)性研究[D];河北醫(yī)科大學(xué);2015年

9 劉兵;SENP1表達(dá)水平對(duì)人腦膠質(zhì)瘤發(fā)生發(fā)展的作用機(jī)制及其相關(guān)性[D];河北醫(yī)科大學(xué);2015年

10 李文華;Slit2/Robo1在人腦膠質(zhì)瘤中的表達(dá)及臨床意義[D];河北醫(yī)科大學(xué);2015年

，

本文編號(hào)：1712686